Recently, Cephalon, Inc. (CEPH) filed a patent infringement lawsuit against generic player Teva Pharmaceuticals (TEVA), which is seeking to market a generic version of Cephalon’s sleep franchise product, Nuvigil.

The lawsuit was filed in response to a Paragraph IV Certification Notice Letter received by Cephalon in October regarding an Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration (FDA) by Teva. Teva is seeking approval for its generic version of the 50 mg, 100 mg, 150 mg, 200 mg and 250 mg dosage strengths of Nuvigil.

Nuvigil (armodafinil) is the follow-on version of Provigil (modafinil), which contributed about 50% to revenues in 2008. With Provigil slated to face generics from 2012, Cephalon is looking to protect its sleep franchise sales by switching patients to Nuvigil.

Cephalon is aggressively promoting Nuvigil, which was launched in June 2009. The company has taken several initiatives to ensure the smooth transition of users to Nuvigil, which has been priced at a significant discount to Provigil. Besides this, Cephalon is working on gaining approval for additional indications for Nuvigil, which should help expand the market for the product and drive sales for the franchise. We expect the Provigil/Nuvigil franchise to cross $1 billion in sales in 2009.

Given the importance of the sleep franchise, the filing of a patent infringement lawsuit by Cephalon was in-line with expectations. We expect the company to vigorously defend its patent. Cephalon has a three-year period of marketing exclusivity for Nuvigil that extends until June 15, 2010. The entry of generic versions of Nuvigil would have a devastating impact on sales.

We currently have a Neutral recommendation on the stock. We expect investor focus to remain on Cephalon’s emerging oncology pipeline, Amrix, and the conversion of patients to Nuvigil.

Zacks Investment Research

1. (ABT) Abbott Laboratories Settles Dispute with Teva Pharmaceutical IndustriesIn a filing with the U.S. Securities and Exchange Commission (SEC), Abbott Laboratories Inc. (ABT)...
2. (CEPH) Cephalon Settles Barr Pharmaceuticals ChallengeEarlier this month, Cephalon Inc. (CEPH) announced that it has settled its patent infringement case...
3. (TEVA) Teva Pharmaceutical Industries Reports Strong QuarterTeva Pharmaceutical Industries Ltd. (TEVA) reported earnings of 89 cents in the third quarter of...
4. ($CEPH) Cephalon Beats Forecasts – Provides OutlookCephalon Inc. (CEPH) reported strong third-quarter earnings of $1.62 per share that easily surpassed the...
5. (CEPH) Cephalon’s Nuvigil Faces Generic Threat Teva PharmaceuticalsCephalon, Inc. (CEPH) recently received a Paragraph IV Certification Notice Letter regarding an Abbreviated New...
6. (TEVA) Teva Pharmaceuticals’ Copaxone ChallengedShares of generic player Teva Pharmaceuticals, Inc. (TEVA) were down approximately 2% on news regarding...

Search Posts by Tag: CEPH | Cephalon Inc. | TEVA | Teva Pharmaceutical Industries Limited | Drug Manufacturers - Other | Healthcare

RSS Feeds by Tag: CEPH | Cephalon Inc. | TEVA | Teva Pharmaceutical Industries Limited | Drug Manufacturers - Other | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author